Analyst Ratings For Arbutus Biopharma Corp (NASDAQ:ABUS)
Today, Chardan Capital reiterated its Buy rating on Arbutus Biopharma Corp (NASDAQ:ABUS) with a price target of $5.00.
There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Arbutus Biopharma Corp (NASDAQ:ABUS) is Hold with a consensus target price of $6.3333 per share, a potential 170.66% upside.
Some recent analyst ratings include
- 7/16/2019-Arbutus Biopharma Corp (NASDAQ:ABUS) had its Buy rating reiterated by Chardan Capital with a $5.00 price target
- 3/11/2019-Arbutus Biopharma Corp (NASDAQ:ABUS) had its Hold rating reiterated by Echelon Wealth Partners
- 10/16/2018-Arbutus Biopharma Corp (NASDAQ:ABUS) gets upgraded to Buy by B. Riley with a price target of $9.00
- 10/15/2018-Arbutus Biopharma Corp (NASDAQ:ABUS) gets upgraded to Neutral by Wedbush with a price target of $5.00
- 11/7/2017-Arbutus Biopharma Corp (NASDAQ:ABUS) had its Market Perform rating reiterated by Leerink Swann with a $5.00 price target
- On 8/13/2018 Michael J Sofia, Insider, sold 4,250 with an average share price of $9.51 per share and the total transaction amounting to $40,417.50.
- On 7/11/2018 Michael J Sofia, Insider, sold 10,000 with an average share price of $10.00 per share and the total transaction amounting to $100,000.00.
- On 7/9/2018 Michael J Sofia, Insider, sold 10,000 with an average share price of $8.91 per share and the total transaction amounting to $89,100.00.
- On 7/5/2018 Michael J Sofia, Insider, sold 20,000 with an average share price of $8.20 per share and the total transaction amounting to $164,000.00.
- On 7/3/2018 Michael J Sofia, Insider, sold 10,000 with an average share price of $8.00 per share and the total transaction amounting to $80,000.00.
- On 10/3/2017 Michael J Sofia, Insider, sold 10,000 with an average share price of $8.00 per share and the total transaction amounting to $80,000.00.
- On 8/15/2017 Michael J Sofia, Insider, sold 30,000 with an average share price of $3.70 per share and the total transaction amounting to $111,000.00.
About Arbutus Biopharma Corp (NASDAQ:ABUS)
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. Read More…
Recent Trading Activity for Arbutus Biopharma Corp (NASDAQ:ABUS)
Shares of Arbutus Biopharma Corp closed the previous trading session at 2.34 −0.060 2.50% with 2.45 shares trading hands.